159 related articles for article (PubMed ID: 36155854)
1. Covid-19 third vaccination during pregnancy: maternal and neonatal outcomes-a retrospective study.
Rottenstreich M; Rotem R; Wiener-Well Y; Grisaru-Granovsky S; Sela HY
Arch Gynecol Obstet; 2023 Oct; 308(4):1197-1205. PubMed ID: 36155854
[TBL] [Abstract][Full Text] [Related]
2. Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study.
Rottenstreich M; Sela HY; Rotem R; Kadish E; Wiener-Well Y; Grisaru-Granovsky S
BJOG; 2022 Jan; 129(2):248-255. PubMed ID: 34554630
[TBL] [Abstract][Full Text] [Related]
3. Third trimester messenger RNA COVID-19 booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth.
Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Lahav Sher M; Barsha H; Shalabna E; Zolotarevsky A; Lavie O; Kedar R; Riskin-Mashiah S
Eur J Obstet Gynecol Reprod Biol; 2022 Jul; 274():148-154. PubMed ID: 35653903
[TBL] [Abstract][Full Text] [Related]
4. Obstetric and Early Neonatal Outcomes Following Second and Third COVID-19 Vaccination in Pregnancy.
Peretz-Machluf R; Gilboa M; Bookstein-Peretz S; Segal O; Regev N; Meyer R; Regev-Yochay G; Yinon Y; Toussia-Cohen S
Isr Med Assoc J; 2024 Jan; 26(1):12-17. PubMed ID: 38420636
[TBL] [Abstract][Full Text] [Related]
5. Maternal and Neonatal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G Levels After the Pfizer-BioNTech Booster Dose for Coronavirus Disease 2019 (COVID-19) Vaccination During the Second Trimester of Pregnancy.
Kugelman N; Nahshon C; Shaked-Mishan P; Kleifeld S; Cohen N; Sher ML; Zahran H; Barsha H; Assaf W; Shalabna E; Stein N; Lavie O; Kedar R; Riskin-Mashiah S
Obstet Gynecol; 2022 Aug; 140(2):187-193. PubMed ID: 35852268
[TBL] [Abstract][Full Text] [Related]
6. Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy.
Dick A; Rosenbloom JI; Karavani G; Gutman-Ido E; Lessans N; Chill HH
Am J Obstet Gynecol MFM; 2022 Jul; 4(4):100637. PubMed ID: 35398583
[TBL] [Abstract][Full Text] [Related]
7. Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy.
Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Sher ML; Gruber M; Marom I; Zolotarevsky A; Lavie O; Damti A; Zilberlicht A; Bardicef M; Kedar R
JAMA Pediatr; 2022 Mar; 176(3):290-295. PubMed ID: 34932066
[TBL] [Abstract][Full Text] [Related]
8. Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
Yamin D; Yechezkel M; Arbel R; Beckenstein T; Sergienko R; Duskin-Bitan H; Yaron S; Peretz A; Netzer D; Shmueli E
Lancet Infect Dis; 2023 Oct; 23(10):1130-1142. PubMed ID: 37352878
[TBL] [Abstract][Full Text] [Related]
9. Effect of COVID-19 vaccination and booster on maternal-fetal outcomes: a retrospective cohort study.
Piekos SN; Hwang YM; Roper RT; Sorensen T; Price ND; Hood L; Hadlock JJ
Lancet Digit Health; 2023 Sep; 5(9):e594-e606. PubMed ID: 37537121
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy Outcomes in Patients After Completion of the mRNA Coronavirus Disease 2019 (COVID-19) Vaccination Series Compared With Unvaccinated Patients.
Morgan JA; Biggio JR; Martin JK; Mussarat N; Elmayan A; Chawla HK; Kandalaft S; Magalski GR; Puri P; Williams FB
Obstet Gynecol; 2023 Mar; 141(3):555-562. PubMed ID: 36735413
[TBL] [Abstract][Full Text] [Related]
11. Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.
Spitzer A; Angel Y; Marudi O; Zeltser D; Saiag E; Goldshmidt H; Goldiner I; Stark M; Halutz O; Gamzu R; Slobodkin M; Amrami N; Feigin E; Elbaz M; Furman M; Bronstein Y; Chikly A; Eshkol A; Furer V; Mayer T; Meijer S; Melloul A; Mizrahi M; Yakubovsky M; Rosenberg D; Safir A; Spitzer L; Taleb E; Elkayam O; Silberman A; Eviatar T; Elalouf O; Levinson T; Pozyuchenko K; Itzhaki-Alfia A; Sprecher E; Ben-Ami R; Henig O
JAMA; 2022 Jan; 327(4):341-349. PubMed ID: 35006256
[TBL] [Abstract][Full Text] [Related]
12. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.
Moro PL; Olson CK; Zhang B; Marquez P; Strid P
Obstet Gynecol; 2022 Sep; 140(3):421-427. PubMed ID: 35926203
[TBL] [Abstract][Full Text] [Related]
13. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose.
Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O
Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228
[TBL] [Abstract][Full Text] [Related]
14. Prenatal maternal COVID-19 vaccination and pregnancy outcomes.
Wainstock T; Yoles I; Sergienko R; Sheiner E
Vaccine; 2021 Oct; 39(41):6037-6040. PubMed ID: 34531079
[TBL] [Abstract][Full Text] [Related]
15. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 vaccination during pregnancy: coverage and safety.
Blakeway H; Prasad S; Kalafat E; Heath PT; Ladhani SN; Le Doare K; Magee LA; O'Brien P; Rezvani A; von Dadelszen P; Khalil A
Am J Obstet Gynecol; 2022 Feb; 226(2):236.e1-236.e14. PubMed ID: 34389291
[TBL] [Abstract][Full Text] [Related]
17. Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study.
Yechezkel M; Mofaz M; Painsky A; Patalon T; Gazit S; Shmueli E; Yamin D
Lancet Respir Med; 2023 Feb; 11(2):139-150. PubMed ID: 36410364
[TBL] [Abstract][Full Text] [Related]
18. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine.
Patalon T; Gazit S; Pitzer VE; Prunas O; Warren JL; Weinberger DM
JAMA Intern Med; 2022 Feb; 182(2):179-184. PubMed ID: 34846533
[TBL] [Abstract][Full Text] [Related]
19. Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers.
Angel Y; Spitzer A; Henig O; Saiag E; Sprecher E; Padova H; Ben-Ami R
JAMA; 2021 Jun; 325(24):2457-2465. PubMed ID: 33956048
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
